It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their ...

Antiobesity medications tirzepatide and semaglutide offer long-term health benefits but are not cost-effective.

As China embarks on its three-year "weight management" campaign, Novo Nordisk has stepped forward with its powerful tools to ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Increased antibiotic use can lead, seemingly paradoxically, to more problematic infections, as the bacteria evolve to resist ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

They’re expensive and aren’t a short-term fix, but Ozempic and Wegovy show great promise in regulating weight. | Opinion ...